Guggenheim Partners
Tracked across 36 events · 291 articles · First seen Mar 04, 2025 · Last active Aug 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Guggenheim Partners acted as a lead book-running manager, earning fees and demonstrating its capability in executing biotech IPOs. The successful offering supports its investment banking business.
Aug 07, 2026 · 8 articles
Business
Impact: Guggenheim Partners acted as the sole book-running manager for the IPO of BHAV Acquisition Corp, facilitating the offering and demonstrating its role in capital markets.
Apr 16, 2026 · 6 articles
Business
Impact: Guggenheim Partners is acting as a book-running manager for the public offering by Forte Biosciences.
Apr 08, 2026 · 7 articles
Business
Impact: Guggenheim Partners is acting as a joint book-running manager for the public offering of Spyre Therapeutics' common stock.
Apr 13, 2026 · 7 articles
Business
Impact: Guggenheim analyst John DiFucci upgraded ServiceNow from Neutral to Buy, a valuation-driven call that contributed to a 6.8% stock jump.
Jun 26, 2026 · 6 articles
Business
Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of common shares and warrants. The offering consists of 3,870,500 common shares and accompanying warrants to purchase an…
Impact: Guggenheim Partners is the sole book-running manager for the offering, earning underwriting fees and strengthening its relationship with Edesa.
Aug 19, 2026 · 12 articles
Regulatory
Impact: Guggenheim Partners analysts published a report exposing the limited experience and resources of ENTRA1 Energy LLC, contributing to the stock drop of NuScale Power.
Feb 19, 2026 · 26 articles
Business
Impact: Guggenheim Partners is acting as a book-running manager for the public offering by Sophia Genetics.
Jun 16, 2026 · 7 articles
Business
Impact: Guggenheim Partners is a joint book-running manager, participating in the offering and earning fees.
Aug 04, 2026 · 6 articles
Business
Impact: Guggenheim Partners' Executive Chairman, Alan Schwartz, participated in a fireside chat with Ahmed Jasim Al Zaabi at the Milken Institute Global Conference, discussing global financial innovation.
May 13, 2026 · 8 articles
Business
Impact: Guggenheim Partners is acting as a joint bookrunning manager for Neurogene's public offering.
Jun 30, 2026 · 6 articles
Business
Impact: Guggenheim Partners is acting as an active book-running manager for the initial public offering of Parabilis Medicines.
Jun 10, 2026 · 7 articles
Business
Impact: Guggenheim Securities is a co-global coordinator and joint bookrunner, involved in the IPO.
Jul 20, 2026 · 6 articles
Business
Impact: Guggenheim Partners acted as a joint book-running manager, earning underwriting fees.
Jul 06, 2026 · 25 articles
Business
Impact: Guggenheim Partners acted as a bookrunner for the offering.
Apr 06, 2026 · 8 articles
Business
Impact: Guggenheim Securities is acting as a bookrunner for Eric Rock's IPO.
Jun 01, 2026 · 7 articles
Business
Impact: Guggenheim Securities acted as joint book-running manager for the offering, earning underwriting fees.
Jul 14, 2026 · 7 articles
Regulatory
Impact: Guggenheim Partners was engaged by Sleep Number Corporation to evaluate strategic and financing options, which was cited as a reason for suspending financial guidance.
May 19, 2026 · 6 articles
Business
Impact: Guggenheim Securities served as exclusive financial advisor to Forte Biosciences.
Jul 27, 2026 · 6 articles
Business
Olivier Pomel, CEO of Datadog, sold shares of Class A Common Stock on July 13 and July 23, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025. The July 13 sale…
Impact: Guggenheim raised its price target to $300, citing strong revenue growth expectations and early adoption of Bits AI.
Jul 17, 2026 · 7 articles
Business
Impact: Acted as financial advisor to Maverick in the transaction.
Aug 03, 2026 · 6 articles
Business
Guidewire Software CEO Michael Rosenbaum sold 1,200 shares of Guidewire Software common stock on multiple occasions during 2026, including on July 13, July 27, and August 3, under a pre-arranged Rule 10b5-1 trading plan adopted…
Impact: Guggenheim Partners initiated coverage with a Buy rating and a $180 price target, highlighting Guidewire's strong position in the P&C insurance sector.
Jul 14, 2026 · 6 articles
Business
Zentalis Pharmaceuticals, a clinical oncology company, announced the pricing of an underwritten public offering of 23 million shares of common stock at $3.50 per share, expecting gross proceeds of approximately $80.5 million. The offering is…
Impact: Guggenheim Partners acts as a joint bookrunner, earning underwriting fees.
Aug 13, 2026 · 6 articles
Business
Impact: Guggenheim Securities is a joint lead book-running manager for the offering.
Apr 20, 2026 · 7 articles
Business
Impact: Guggenheim Securities acted as additional bookrunning manager, earning underwriting fees.
Jul 20, 2026 · 19 articles
Business
Impact: Guggenheim Partners, LLC is serving as a financial advisor to MiNK Therapeutics.
Apr 06, 2026 · 6 articles
Business
Impact: Acted as exclusive financial advisor to Mission.
Jul 17, 2026 · 6 articles
Business
Impact: Guggenheim Partners participated in the analyst Q&A, inquiring about deal structure and retention rates.
Jul 22, 2026 · 6 articles
Business
Impact: Acted as financial advisor to Blackstone in the transaction.
Jul 30, 2026 · 8 articles
Business
Datadog director Harshit Agarwal sold 20,000 shares of Class A common stock on multiple occasions in mid-2026, including July 16 and July 23, under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026.…
Impact: Guggenheim increased its price target to $300, citing positive growth outlook and early adoption of Bits AI.
Jul 28, 2026 · 6 articles
+ 6 more events
View on Dashboard
40
Guggenheim Partners raised price target DatadogDatadog CEO Pomel sells shares
30
Guggenheim Partners raised price target DatadogDatadog Director Amit...
30
Guggenheim Partners initiated coverage Guidewire SoftwareGuidewire CEO Rosenbaum...
30
Edesa Biotech granted underwriter option Guggenheim PartnersEdesa Biotech $25M Public Offering
ERGEN INTELLIGENCE
Track Guggenheim Partners live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard